<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nagaraju GP</submitter><funding>The University of Alabama at Birmingham</funding><funding>Comprehensive Cancer Center, University of Chicago Medical Center</funding><funding>NCI NIH HHS</funding><funding>Morningside Foundation</funding><funding>University of Alabama</funding><pagination>101881</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11866435</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(1)</volume><pubmed_abstract>Pancreatic ductal adenocarcinoma (PDAC) has a minimal (&lt;15%) 5-year existence, in part due to resistance to chemoradiotherapy. Previous research reveals the impact of paricalcitol (P) and hydroxychloroquine (H) on altering the lysosomal fusion, decreasing stromal burden, and triggering PDAC to chemotherapies. This investigation aims to elucidate the molecular properties of the H and P combination and their potential in sensitizing PDAC to gemcitabine (G). PH potentiates the effects of G in in vitro, orthotopic mouse models, and a patient-derived xenograft model of PDAC. Proteomic and single-cell RNA sequencing (RNA-seq) analyses reveal that GPH treatment upregulates autophagy and endoplasmic reticulum (ER) stress-related transcripts. GPH treatment decreases the number of Ki67, fibroblast-a</pubmed_abstract><journal>Cell reports. Medicine</journal><pubmed_title>Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.</pubmed_title><pmcid>PMC11866435</pmcid><funding_grant_id>P30 CA082709</funding_grant_id><funding_grant_id>5P30CAO13148-47</funding_grant_id><pubmed_authors>Golivi Y</pubmed_authors><pubmed_authors>Foote JB</pubmed_authors><pubmed_authors>Manne U</pubmed_authors><pubmed_authors>Masood A</pubmed_authors><pubmed_authors>Reddy SP</pubmed_authors><pubmed_authors>Akce M</pubmed_authors><pubmed_authors>Bandi DSR</pubmed_authors><pubmed_authors>Yoon KJ</pubmed_authors><pubmed_authors>Alese OB</pubmed_authors><pubmed_authors>Herting C</pubmed_authors><pubmed_authors>El-Rayes BF</pubmed_authors><pubmed_authors>Sarvesh S</pubmed_authors><pubmed_authors>Carstens JL</pubmed_authors><pubmed_authors>Bhasin MK</pubmed_authors><pubmed_authors>Switchenko J</pubmed_authors><pubmed_authors>Nagaraju GP</pubmed_authors><pubmed_authors>Khaliq AM</pubmed_authors><pubmed_authors>Sukhatme VP</pubmed_authors><pubmed_authors>Saddala MS</pubmed_authors><pubmed_authors>Lesinski GB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.</name><description>Pancreatic ductal adenocarcinoma (PDAC) has a minimal (&lt;15%) 5-year existence, in part due to resistance to chemoradiotherapy. Previous research reveals the impact of paricalcitol (P) and hydroxychloroquine (H) on altering the lysosomal fusion, decreasing stromal burden, and triggering PDAC to chemotherapies. This investigation aims to elucidate the molecular properties of the H and P combination and their potential in sensitizing PDAC to gemcitabine (G). PH potentiates the effects of G in in vitro, orthotopic mouse models, and a patient-derived xenograft model of PDAC. Proteomic and single-cell RNA sequencing (RNA-seq) analyses reveal that GPH treatment upregulates autophagy and endoplasmic reticulum (ER) stress-related transcripts. GPH treatment decreases the number of Ki67, fibroblast-a</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2026-05-26T14:01:21.004Z</modification><creation>2025-04-04T13:10:59.497Z</creation></dates><accession>S-EPMC11866435</accession><cross_references><pubmed>39730001</pubmed><doi>10.1016/j.xcrm.2024.101881</doi></cross_references></HashMap>